Phase 1/2 study of apatorsen for intravesical administration in combination with Bacillus Calmette-Guerin (BCG) treatment in patients with non-muscle invasive bladder cancer

Trial Profile

Phase 1/2 study of apatorsen for intravesical administration in combination with Bacillus Calmette-Guerin (BCG) treatment in patients with non-muscle invasive bladder cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs Apatorsen (Primary) ; BCG
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors OncoGenex Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top